Development and validation of bioanalytical methods for the determination of the drug and/or its metabolite/s in a biological matrix in accordance with the EMA/FDA guidelines, completed with a validation report;

Development and validation of bioanalytical methods on HPLC-MS/MS systems for determining such components as:

• Difficult endogenous, reactive or unstable analytes in biological fluids;
• Ultrahigh sensitivity assays with pg/ml lower limits of quantification (LLOQ);
• Analysis of samples in several biological species and matrices;
• Analytes requiring derivatization during sample preparation;
• Analysis of chiral compounds;

Full bioanalytical service offering of PK for small molecules (up to 1000 Da);

Development of analytical methods for the determination of small molecules and endogenous components in dried blood spots (Whatman 903 dbs cards, VAMS);

Analytical supporting in therapeutic drug monitoring;

Drug development supporting and consulting;

Bioanalytical method development supporting and consulting;